Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ioannis Ioannidis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Cyprus, 2109 Nicosia, Cyprus. Hauptthemen laut MEDLINE: Scandium, Radioisotopes, Chelating Agents, Radiopharmaceuticals. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Cyprus, Postgraduate Research Institute of Science, Technology, Environment and Medicine, a non-profit, charitable organization.
Abstract (Originalsprache)
Scandium (Sc) isotopes have recently attracted significant attention in the search for new radionuclides with potential uses in personalized medicine, especially in the treatment of specific cancer patient categories. In particular, Sc-43 and Sc-44, as positron emitters with a satisfactory half-life (3.9 and 4.0 h, respectively), are ideal for cancer diagnosis via Positron Emission Tomography (PET). On the other hand, Sc-47, as an emitter of beta particles and low gamma radiation, may be used as a therapeutic radionuclide, which also allows Single-Photon Emission Computed Tomography (SPECT) imaging. As these scandium isotopes follow the same biological pathway and chemical reactivity, they appear to fit perfectly into the “theranostic pair” concept. A step-by-step description, initiating from the moment of scandium isotope production and leading up to their preclinical and clinical trial applications, is presented. Recent developments related to the nuclear reactions selected and employed to produce the radionuclides Sc-43, Sc-44, and Sc-47, the chemical processing of these isotopes and the main target recovery methods are also included. Furthermore, the radiolabeling of the leading chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and its structural analogues with scandium is also discussed and the advantages and disadvantages of scandium complexation are evaluated. Finally, a review of the preclinical studies and clinical trials involving scandium, as well as future challenges for its clinical uses and applications, are presented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Cyprus, 2109 Nicosia, Cyprus.
- Postgraduate Research Institute of Science, Technology, Environment and Medicine, 3021 Limassol, Cyprus.
ORCID-Profile: Ioannis Ioannidis, Savvas N Georgiades, Ioannis Pashalidis, George J Kontoghiorghes
Förderung
- University of Cyprus
- Postgraduate Research Institute of Science, Technology, Environment and Medicine
- a non-profit, charitable organization
Zitieren
APA
Ioannidis, I., Lefkaritis, G., Georgiades, S. N., Pashalidis, I., & Kontoghiorghes, G. J. (2024). Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115954
Vancouver
Ioannidis I, Lefkaritis G, Georgiades SN, Pashalidis I, Kontoghiorghes GJ. Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115954
BibTeX
@article{Ioannidis2024,
author = {Ioannidis, Ioannis and Lefkaritis, George and Georgiades, Savvas N and Pashalidis, Ioannis and Kontoghiorghes, George J},
title = {Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115954}
}
EUVIMED